Phio Pharmaceuticals Corp. announced on October 16, 2024, that it was presenting data about its INTASYL compound PH-894 at the American Society of Gene & Cell Therapy's (ASGCT's) 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focused on PH-894's ability to potently and specifically silence BRD4 in Natural Killer (NK) cells. This mechanism is designed to improve the functionality and cytotoxicity of NK cells, which are crucial for the body's anti-cancer defense.
The data presented highlighted PH-894 as a promising approach for enhancing NK cell-based immunotherapies. Silencing BRD4 with INTASYL compounds supports further exploration of this target in the development of new NK cell-based cancer treatments. This demonstrates the versatility of Phio's INTASYL technology in targeting specific proteins to improve immune cell function.
The presentation at a specialized conference like ASGCT underscores the scientific interest and potential impact of PH-894 in the field of gene and cell therapies for cancer. It provides a platform for Phio to share its research findings with leading experts and advance the understanding of its proprietary technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.